Aviva
MRNA icon

Aviva’s Moderna MRNA Stock Holding History

Aviva’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,398
Closed -$342K – 907
2025
Q2 		$342K Sell
12,398
-213,362
-95% -$5.62M ﹤0.01% 867
2025
Q1 		$6.4M Buy
225,760
+27,587
+14% +$979K 0.02% 514
2024
Q4 		$8.24M Sell
198,173
-51,303
-21% -$2.45M 0.02% 477
2024
Q3 		$16.7M Buy
249,476
+82,579
+49% +$7.58M 0.04% 371
2024
Q2 		$19.8M Buy
166,897
+54,766
+49% +$6.93M 0.05% 349
2024
Q1 		$11.9M Sell
112,131
-34,947
-24% -$3.52M 0.04% 426
2023
Q4 		$14.6M Buy
147,078
+35,310
+32% +$2.97M 0.05% 386
2023
Q3 		$11.5M Buy
111,768
+36,881
+49% +$4.11M 0.05% 405
2023
Q2 		$9.1M Sell
74,887
-139,116
-65% -$18.6M 0.04% 440
2023
Q1 		$32.9M Buy
214,003
+48,554
+29% +$8.01M 0.15% 181
2022
Q4 		$29.7M Buy
165,449
+3,630
+2% +$594K 0.15% 171
2022
Q3 		$19.1M Sell
161,819
-22,042
-12% -$3.34M 0.11% 251
2022
Q2 		$26.3M Buy
183,861
+74,156
+68% +$10.6M 0.14% 178
2022
Q1 		$18.9M Buy
109,705
+55,118
+101% +$9.28M 0.09% 255
2021
Q4 		$13.9M Sell
54,587
-4,252
-7% -$1.24M 0.06% 314
2021
Q3 		$22.6M Sell
58,839
-50,133
-46% -$18.5M 0.1% 203
2021
Q2 		$25.6M Buy
108,972
+13,910
+15% +$2.49M 0.11% 192
2021
Q1 		$12.4M Buy
95,062
+1,110
+1% +$161K 0.06% 291
2020
Q4 		$9.81M Buy
93,952
+3,689
+4% +$373K 0.05% 325
2020
Q3 		$6.39M Buy
+90,263
New +$6.29M 0.04% 391

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Aviva's MRNA Position: Q3 2025 in Review

Aviva sold out of Moderna (MRNA) in Q3 2025, closing a stake of 12,398 shares — an estimated $342K sold.

Aviva first reported a position in MRNA in Q3 2020 and held it in 20 quarters. The position peaked at $32.9M in Q1 2023. 643 funds tracked by Wall St. Rank hold MRNA as of Q3 2025.

  • Aviva reported no remaining Moderna position as of Q3 2025 after selling out during the quarter.
  • Aviva sold 12,398 Moderna shares in Q3 2025, an estimated $342K.
  • Aviva first reported a position in Moderna in Q3 2020 and held it in 20 quarters.
  • Aviva's Moderna position peaked at $32.9M in Q1 2023.
  • 643 funds tracked by Wall St. Rank held Moderna as of Q3 2025.

Based on Aviva's 13F filing for Q3 2025, filed 13 Nov 2025.